Get started
Editas Medicine, Inc.Editas Medicine, Inc.Editas Medicine, Inc.

Editas Medicine, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

EDIT chart


Full chart

EDIT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪108.82 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.88 USD
Net income (FY)
‪−237.09 M‬ USD
Revenue (FY)
‪32.31 M‬ USD
Shares float
‪82.93 M‬
Beta (1Y)
1.98

Employees


Employees (FY)
246
Change (1Y)
−19 −7.17%
Revenue / Employee (1Y)
‪131.36 K‬ USD
Net income / Employee (1Y)
‪−963.79 K‬ USD

About Editas Medicine, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Gilmore O’Neill
Website
editasmedicine.com
Headquarters
Cambridge
Founded
2013
FIGI
BBG005MX5GZ2
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EDIT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as EDIT.

Frequently Asked Questions


The current price of EDIT is 1.32 USD — it has increased by 1.54% in the past 24 hours. Watch Editas Medicine, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Editas Medicine, Inc. stocks are traded under the ticker EDIT.
EDIT stock has risen by 30.69% compared to the previous week, the month change is a −7.69% fall, over the last year Editas Medicine, Inc. has showed a −79.79% decrease.
We've gathered analysts' opinions on Editas Medicine, Inc. future price: according to them, EDIT price has a max estimate of 8.00 USD and a min estimate of 1.00 USD. Watch EDIT chart and read a more detailed Editas Medicine, Inc. stock forecast: see what analysts think of Editas Medicine, Inc. and suggest that you do with its stocks.
EDIT reached its all-time high on Jan 8, 2021 with the price of 99.95 USD, and its all-time low was 0.91 USD and was reached on Apr 7, 2025. View more price dynamics on EDIT chart.
See other stocks reaching their highest and lowest prices.
EDIT stock is 12.71% volatile and has beta coefficient of 1.98. Track Editas Medicine, Inc. stock price on the chart and check out the list of the most volatile stocks — is Editas Medicine, Inc. there?
Today Editas Medicine, Inc. has the market capitalization of ‪110.50 M‬, it has decreased by −11.50% over the last week.
Yes, you can track Editas Medicine, Inc. financials in yearly and quarterly reports right on TradingView.
Editas Medicine, Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
EDIT earnings for the last quarter are −0.55 USD per share, whereas the estimation was −0.38 USD resulting in a −45.75% surprise. The estimated earnings for the next quarter are −0.56 USD per share. See more details about Editas Medicine, Inc. earnings.
Editas Medicine, Inc. revenue for the last quarter amounts to ‪30.60 M‬ USD, despite the estimated figure of ‪29.76 M‬ USD. In the next quarter, revenue is expected to reach ‪714.64 K‬ USD.
EDIT net income for the last quarter is ‪−45.40 M‬ USD, while the quarter before that showed ‪−62.14 M‬ USD of net income which accounts for 26.95% change. Track more Editas Medicine, Inc. financial stats to get the full picture.
No, EDIT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 246 employees. See our rating of the largest employees — is Editas Medicine, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Editas Medicine, Inc. EBITDA is ‪−233.11 M‬ USD, and current EBITDA margin is −721.39%. See more stats in Editas Medicine, Inc. financial statements.
Like other stocks, EDIT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Editas Medicine, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Editas Medicine, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Editas Medicine, Inc. stock shows the sell signal. See more of Editas Medicine, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.